- July 1, 2026
- Posted by: admin
- Category: Blog
Turkey has one of the most strategically important healthcare markets in its region. It has a large population, a broad public reimbursement system, strong domestic manufacturers, and growing interest from international pharmaceutical companies. However, the country’s medicine pricing framework also creates a unique commercial challenge. The reason is simple: medicine prices are not freely determined by companies. Instead, they are controlled through a reference pricing model, public reimbursement rules, regulated margins, and a special Euro conversion mechanism.
For foreign pharmaceutical companies, this mechanism often becomes one of the most important issues in market entry planning. A product may have regulatory approval, strong medical demand, and a clear patient need. Yet the commercial model may still become difficult if the official Euro rate used for pricing remains far below the market exchange rate. Therefore, investors, marketing authorization holders, distributors, and public affairs teams need to understand both the legal structure and the business consequences of this system.
This article explains how the Turkish pharmaceutical pricing model works, why the Euro conversion mechanism matters, and how companies can manage the related risks. It also places the topic within the wider Pharmaceutical industry in Turkey, including market access, government relations, reimbursement, localization, and investment planning.
How Pharmaceutical Pricing in Turkey Works
The Turkish medicine pricing system combines external reference pricing with a regulated Turkish lira conversion model. In practice, the authorities look at reference prices in selected European countries and then convert the relevant Euro-based price into Turkish lira by using an official conversion value. This official value does not automatically equal the daily market exchange rate.
The Turkish Medicines and Medical Devices Agency, known as TİTCK, plays a central role in price approval, product registration, licensing, and technical evaluation. Companies entering the market should also examine the product registration process because pricing cannot be separated from regulatory strategy. For this reason, many foreign companies review Drug Registration in Turkey and Market Authorization before they make final pricing assumptions.
Turkey’s pricing system aims to protect public budgets and patient access. Since the Social Security Institution is the dominant payer for reimbursed medicines, the government has a strong interest in keeping prices predictable. However, the same system also creates pressure for companies when inflation, production costs, import costs, and exchange rates move faster than the official conversion rate.
Why the Euro Conversion Mechanism Matters
The Euro conversion mechanism is one of the most sensitive parts of the Turkish pricing framework. Many imported medicines depend on foreign currency costs. Active pharmaceutical ingredients, finished products, quality control services, packaging materials, technology licenses, and international logistics may all be linked to Euro or US dollar expenses.
However, medicine prices in Turkey are converted into Turkish lira through an official pharmaceutical Euro value. When this official value stays below the actual market Euro rate, companies face a gap between revenue and cost. This gap can reduce profitability, delay launches, limit supply, or make some products commercially unattractive.
The issue becomes even more important for innovative medicines, orphan drugs, biologics, biosimilars, oncology products, and therapies with complex supply chains. These products often require high investment, strict temperature control, pharmacovigilance infrastructure, and specialized market access planning. As a result, pricing uncertainty can affect not only commercial returns but also patient access.
Legal and Regulatory Background of the Euro Conversion Mechanism
The pricing of human medicinal products in Turkey is regulated through presidential decisions, communiqués, and administrative decisions. The authorities periodically update the Euro value used for medicine pricing. In recent years, Turkey has revised the system several times to respond to currency volatility and market pressure.
According to recent legal updates, the 2026 framework introduced a revised calculation model. The adjustment coefficient used to determine the pharmaceutical Euro value was increased to 65% of the previous year’s average Euro selling rate published by the Central Bank of the Republic of Türkiye. Transitional values were also introduced for 2026, including a value of TRY 26.8767 until 1 April 2026 and TRY 29.1164 from 1 April 2026 onward. These updates were discussed in legal briefings following the new pricing decision published in 2026.
The Turkish system also includes profit margin rules for wholesalers and pharmacists. These margins affect the price chain from the ex-factory level to the pharmacy retail price. Therefore, companies should not review the Euro conversion value in isolation. They should examine the full price structure, including reference price, conversion value, warehouse margin, pharmacy margin, VAT, reimbursement discount, and public procurement conditions.
Core Challenge: The Gap Between Official and Market Exchange Rates
The main challenge is the difference between the official pharmaceutical Euro value and the actual market exchange rate. When this difference becomes wide, imported products become more expensive to supply, while regulated Turkish lira prices remain relatively low.
This creates several commercial consequences. First, companies may struggle to maintain supply for low-margin products. Second, launch decisions may become more conservative. Third, companies may prefer to prioritize products with stronger strategic value or more flexible pricing potential. Fourth, distributors may demand revised commercial terms because their working capital risk increases. Finally, public authorities may face more pressure from patients, pharmacists, and healthcare professionals when shortages occur.
The Turkish model tries to balance affordability and sustainability. Yet this balance becomes harder when inflation and currency volatility are high. The authorities may increase the official Euro value, but companies may still view the adjustment as partial if the market exchange rate has moved faster.
Impact on Foreign Pharmaceutical Companies
Foreign companies usually evaluate Turkey as part of a regional commercial strategy. The country can serve as a large end market, a regional hub, and a manufacturing base. However, the pricing framework can affect each of these roles.
For an imported product, the pricing gap may reduce the attractiveness of direct sales. For a licensed product, it may change royalty economics. For a local manufacturing project, it may affect cost recovery and investment payback. For a distributor model, it may increase negotiation pressure between the foreign supplier and the Turkish partner.
Foreign investors should also remember that medicine pricing interacts with broader legal and operational issues. A company may need a Turkish entity, regulatory representation, banking structure, tax planning, and local service providers. In many cases, the wider market entry plan includes Business registration in Turkey, local agreements, regulatory filings, and public authority communication.
Impact on Market Access and Reimbursement Strategy
Market access in Turkey requires much more than price approval. Companies must also consider reimbursement listing, public payer expectations, clinical value, budget impact, alternative reimbursement models, and stakeholder communication.
When the regulated price is commercially difficult, companies may need to develop a stronger reimbursement strategy. They may need to show unmet medical need, real-world value, pharmacoeconomic benefit, or public health relevance. In some cases, they may also explore alternative reimbursement arrangements for high-value products.
This is where Government Affairs in Turkey becomes important. Pharmaceutical companies often need structured dialogue with public authorities, industry associations, patient groups, and healthcare stakeholders. A clear government affairs strategy does not replace legal compliance. However, it helps companies explain the public health value of a product and the sustainability problems caused by pricing pressure.
Impact on Supply Continuity and Shortage Risk
Medicine shortages can arise from many factors, including global supply chain problems, manufacturing disruptions, demand spikes, quality issues, and local commercial constraints. In Turkey, the Euro conversion mechanism can add another layer of risk.
If the official price does not cover the economic cost of supply, companies may reduce allocation or delay new shipments. Domestic manufacturers may also face pressure if they import raw materials, APIs, packaging, or machinery. Therefore, the pricing issue does not only affect multinational companies. It can also affect local producers.
Public authorities are aware of this risk. This is why Turkey periodically adjusts the official Euro value and updates thresholds or margins. However, companies still need to monitor profitability product by product. A portfolio-level average can hide serious problems in specific products, especially mature medicines, low-priced products, and products with complex import costs.
Pharmaceutical Pricing in Turkey and the Reference Price System
Turkey uses an external reference pricing logic. In simple terms, the system compares prices in selected reference countries and uses the lowest or relevant reference price as a basis. The Turkish price is then calculated through the local rules.
This system supports public cost control. However, it also creates strategic questions for companies. A price reduction in a reference country may affect Turkey. A launch sequence in Europe may influence the Turkish reference base. A product’s price in Turkey may also matter for companies that monitor international price corridors.
Therefore, companies should not treat Turkey as a standalone pricing decision. They should include Turkey in global price governance. They should also review the interaction between Turkish prices, reference countries, distribution agreements, parallel trade concerns, and regional launch plans.
Commercial Planning for Importers and Distributors
Importers and distributors must manage several practical risks. They buy or source products under foreign currency cost structures. Yet they sell under Turkish lira price controls. This creates foreign exchange exposure, inventory risk, and working capital pressure.
A distributor may need to finance stock before reimbursement collections arrive. It may also need to pay customs, logistics, warehousing, cold chain, and regulatory costs. Because of this, market entry planning often includes banking and payment infrastructure. Foreign investors may also need support for Opening a bank account in Turkey to manage local collections and payments.
Contracts between foreign suppliers and Turkish partners should address price change mechanisms, currency risk, minimum supply commitments, termination rights, stock compensation, regulatory responsibilities, and force majeure scenarios. If the agreement ignores pricing risk, the relationship may become unstable when the official Euro value changes slowly.
Legal Agreements and Risk Allocation
The Euro conversion mechanism should be reflected in commercial agreements. Distribution agreements, license agreements, supply contracts, pharmacovigilance agreements, quality agreements, and service contracts should all align with the pricing reality.
For example, a foreign supplier may want to include a clause that allows renegotiation if the official pharmaceutical Euro value diverges significantly from the market exchange rate. A Turkish distributor may request protection if regulated prices change after it has purchased stock. Both parties may also need rules for reimbursement discounts, mandatory price reductions, public tenders, and delisting risks.
Because these contracts involve local regulation, foreign companies often work with an English speaking lawyer in Turkey. Legal review is especially important when the transaction includes regulated products, public reimbursement exposure, strict compliance obligations, and long-term supply commitments.
Tax, VAT, and Accounting Considerations
Medicine pricing is not only a regulatory issue. It also has tax and accounting consequences. Companies should examine VAT, withholding tax, transfer pricing, invoicing currency, customs valuation, and local accounting rules.
VAT may affect the final price chain and cash flow. For this reason, investors should understand Vat in Turkey before they build a financial model. They should also identify whether the Turkish company, branch, distributor, or representative will become one of the relevant Tax Payers in Turkey.
Transfer pricing can also become sensitive. If a foreign group sells products to its Turkish affiliate, the intercompany price must be defensible. However, the Turkish affiliate may face regulated selling prices. Therefore, the group should align tax documentation with the commercial restrictions of the pharmaceutical market.
Operational Documentation and Local Formalities
Pharmaceutical market entry usually requires significant documentation. Companies may need corporate documents, powers of attorney, notarized signatures, apostilled documents, translated files, regulatory dossiers, GMP documents, authorization letters, and commercial agreements.
In Turkey, notarization remains important for many corporate and legal procedures. Foreign companies should plan for Notaries in Turkey, sworn translations, apostille procedures, and consular legalization when needed. They may also need translation services in Turkey for regulatory, corporate, and legal files.
Small procedural delays can affect launch timing. Therefore, companies should prepare documentation early. This is especially true when the product has a narrow launch window, a reimbursement deadline, or a public tender opportunity.
Investment and Localization Considerations
Turkey has encouraged local production in several healthcare-related areas. For pharmaceutical companies, localization may reduce some currency risks, improve supply security, and strengthen the company’s relationship with public authorities. However, local manufacturing also requires capital, technology transfer, quality systems, and regulatory planning.
Some investors may consider acquiring an existing licensed company, production facility, or distribution platform. In that context, a business for sale in Turkey can become relevant if it provides regulatory infrastructure, licenses, warehouses, or local market access capability.
However, acquisition does not eliminate pricing risk. Buyers must review the target company’s product portfolio, reimbursement position, price approvals, outstanding regulatory obligations, stock levels, and exposure to imported inputs. Due diligence should include financial, legal, regulatory, tax, and operational review.
Strategic Options for Pharmaceutical Companies
Companies cannot control the official Euro conversion value. However, they can manage their exposure. The first step is product-level analysis. Each product should have a clear profit and risk profile under different exchange rate scenarios.
The second step is launch sequencing. Companies may decide to prioritize products with strong reimbursement potential, high medical need, or strategic relevance. They may delay products that cannot support a sustainable price.
The third step is stakeholder communication. Companies should explain supply challenges with data, not emotion. They should present cost structure, patient need, public health value, and international comparisons where appropriate.
The fourth step is contract design. Supply and distribution agreements should include mechanisms for currency pressure, official price changes, reimbursement revisions, stock management, and exceptional circumstances.
The fifth step is operational resilience. Companies should diversify logistics, monitor inventory, improve forecasting, and align local teams with headquarters. In a volatile pricing environment, slow internal decision-making can create avoidable market access problems.
Common Mistakes in Turkish Pharmaceutical Pricing Planning
Assuming the Market Euro Rate Applies Automatically
One of the most common mistakes is assuming that a Euro-based reference price will be converted at the current market exchange rate. This assumption can seriously distort revenue projections. Companies should use the official pharmaceutical Euro value in their model.
Ignoring Reimbursement Discounts
Price approval does not guarantee net revenue. Reimbursement discounts, public payer rules, and institutional purchasing conditions can reduce the effective price. A realistic model must include both gross and net price assumptions.
Separating Regulatory Strategy from Pricing Strategy
Registration, pricing, and reimbursement should move together. If teams work in silos, the company may obtain approval but fail to achieve a viable commercial route.
Using Standard Distribution Agreements
A generic distribution agreement may not address Turkish pharmaceutical pricing risk. Companies should adapt contracts to local regulation, public reimbursement dynamics, and currency exposure.
Future Outlook for the Euro Conversion Mechanism
Turkey will likely continue to balance two priorities: public affordability and market sustainability. On one side, the government must control healthcare spending. On the other side, patients need reliable access to imported, innovative, and essential medicines.
The 2026 changes suggest that policymakers recognize the need for adjustment. The increase of the coefficient to 65%, the transitional Euro values, and the discussion of value-based pricing show that the system is evolving. However, companies should not assume that reform will remove pricing pressure completely.
Value-based pricing may become more important over time, especially for innovative therapies. Alternative reimbursement models may also gain importance for high-cost medicines. Nevertheless, practical implementation will depend on budget capacity, administrative processes, data quality, and stakeholder trust.
How Foreign Investors Should Approach Pharmaceutical Pricing in Turkey
Foreign investors should treat pricing as a core entry issue, not a late-stage administrative step. Before entering Turkey, they should ask several questions. Is the product reimbursable? What is the reference price? What official Euro value applies? What is the expected net price after discounts? Does the product depend on imported inputs? Can local manufacturing improve the model? What happens if the market exchange rate moves sharply?
Investors should also map the relevant authorities and stakeholders. These may include TİTCK, the Ministry of Health, the Social Security Institution, industry associations, distributors, pharmacists, physicians, patient organizations, and public procurement bodies. Official information published by the Turkish Medicines and Medical Devices Agency should be monitored regularly. Companies should also review international healthcare and pharmaceutical indicators through high-authority resources such as the OECD health database and publications.
A serious market entry plan should combine legal, regulatory, financial, tax, and public affairs work. Turkey offers strong potential, but the pricing system requires discipline. Companies that understand the mechanism early can make better investment decisions and avoid costly surprises.
Conclusion: Managing Pricing Risk in a Regulated Market
Turkey remains an important pharmaceutical market with long-term potential. Its population size, healthcare infrastructure, domestic manufacturing capacity, and regional position make it attractive for international companies. However, the Euro conversion mechanism creates a structural challenge that every pharmaceutical company must evaluate carefully.
The official pharmaceutical Euro value can remain below the actual market exchange rate. This gap affects imported products, local manufacturers with foreign currency costs, distributors, investors, and patients. It can influence launch decisions, supply continuity, reimbursement strategy, and contract negotiations.
Companies that want to succeed in Turkey should not view pricing as a narrow technical issue. They should treat it as a strategic market access matter. The best approach combines regulatory planning, financial modeling, legal contract design, government affairs, tax review, and operational risk management.
In short, pharmaceutical pricing in Turkey rewards preparation. Companies that understand the Euro conversion mechanism, monitor regulatory changes, and build flexible strategies will be better positioned to protect both commercial sustainability and patient access.
